BioPharmSignal logoBioPharmSignal

Biotech News

Join Enlivex Therapeutics' Chief Executive Officer for a Live Investor Webinar and Q&A Session on June 25

Enlivex Therapeutics (ENLV)Enlivex TherapeuticsCompany update

Ness-Ziona, Israel, June 20, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company" or "Enlivex"), a clinical-stage macrophage reprogramming immunotherapy company, is pleased to invite investors to a webinar on June 25, 2024, at 4:15 p.m. ET.

The event, hosted by RedChip Companies, will feature...

Related news

ENLVEnlivex Therapeutics2026-07-29 13:00 EST

Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones

ENLVEnlivex Therapeutics2026-07-30 13:00 EST

Enlivex Treasury Portfolio Update: RAIN Trading Volume Reaches $860MM, 622% Month-Over-Month Growth in July vs June

XLOXilio Therapeutics2026-06-29 11:30 EST

Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer

CADLCandel Therapeutics2026-06-25 12:05 EST

Candel Therapeutics Appoints Mark Sims as Chief Commercial Officer

APVOAptevo Therapeutics2026-05-28 12:05 EST

Aptevo Therapeutics Appoints Mary J. Janatpour, Ph.D., as Senior Vice President & Chief Scientific Officer

CMPXCompass Therapeutics2026-05-28 11:30 EST

Compass Therapeutics to Participate in Upcoming June Investor Events

APVOAptevo Therapeutics2026-08-13 20:05 EST

Aptevo Therapeutics Announces Closing of Existing Warrants Exercise and PIPE for $4.5 Million Gross Proceeds

BNTXBioNTech2026-08-03 09:00 EST

BioNTech Announces Appointment of Guido Oelkers to Management Board as Chief Executive Officer

INTSIntensity Therapeutics2026-07-01 12:00 EST

Intensity Therapeutics Provides Mid-Year Update Highlighting Late-Stage Development Programs and Strategic Partnering Opportunities for INT230-6

HOWLWerewolf Therapeutics2026-08-21 12:00 EST

Werewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent Oversubscribed $150 Million Private Placement

View all latest news

Enlivex Therapeutics

Enlivex Therapeutics is an immunotherapy company focused on macrophage reprogramming and inflammation-related disease. Its story is centered on harnessing innate immunity to address hard-to-treat conditions.

Recent company news

ENLVEnlivex Therapeutics2026-07-30 13:00 EST

Enlivex Treasury Portfolio Update: RAIN Trading Volume Reaches $860MM, 622% Month-Over-Month Growth in July vs June

ENLVEnlivex Therapeutics2026-07-29 13:00 EST

Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones

ENLVEnlivex Therapeutics2026-07-29 13:00 EST

Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones

ENLVEnlivex Therapeutics2026-07-28 13:00 EST

Enlivex Announces $400,000,000 Private Placement

ENLVEnlivex Therapeutics2026-07-28 13:00 EST

Enlivex Announces $400,000,000 Private Placement

Stock data

Close
1.47 USD
Market cap
204.87M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States